UPRES EA 1124- Ecole de Santé Publique, Faculté de Médecine, Nancy, France Professor F Guillemin, Ecole de Santé Publique, Faculté de Médecine, 9 Avenue de la Forêt de Haye, BP 184, F 54500 Vandoeuvre ...
Correspondence to Professor Hendrika Bootsma, Department of Rheumatology and Clinical Immunology, University Medical Center Groningen Hanzeplein 1, 9713 GZ, Groningen The Netherland; h.bootsma{at}umcg ...
Background The SRI(4) is a composite endpoint used in SLE clinical trials. A post-hoc analysis of two Phase III studies of belimumab 1 showed that the achievement of an SRI(4) response at 52 weeks is ...
Objectives To update the 2017 European Alliance of Associations for Rheumatology (EULAR) recommendations for treatment of systemic sclerosis (SSc), incorporating new evidence and therapies. Methods An ...
F8: Back to the future: how to mix the old and new treatments for SLE, Sjögren's and APS ...
SpA: Innovative techniques in spondyloarthritis research – Is there light at the end of the tunnel for our patients?
Correspondence to Siri Lillegraven, Department of Rheumatology, Diakonhjemmet Hospital, Box 23 Vinderen, N-0319 Oslo, Norway; siri.lillegraven{at}gmail.com In secondary analyses, focusing on vdHSS and ...
Objectives Sjögren’s disease (SD) is an autoimmune disease affecting the exocrine glands that is associated with autoantibodies against Ro60/SS-A, anti-Ro52/TRIM21, La/SS-B and others. We examined the ...
Objective Considering the diverse aetiologies and immunodysregulatory statuses observed in each patient with rheumatoid arthritis (RA), stratification based on peripheral blood immunophenotyping holds ...
Department of Laboratory Diagnostics, Changzheng Hospital, Second Military Medical University, Shanghai, China Correspondence to Dr Yang Zaixing and Professor Renqian Zhong, Department of Laboratory ...
Objectives Knee osteoarthritis (KOA) is a leading cause of global disability with conventional exercise yielding only modest improvements. Here we aimed to investigate the benefits of integrating ...
‘Poly-refractory’ disease affects 2.7% of patients with rheumatoid arthritis (RA) who have failed different groups of biologic disease-modifying antirheumatic drugs (b-DMARDS) and targeted synthetic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results